Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Tight liquidity NBB
Cash and receivables cover 46 % of short-term debt in 2024; threshold 65 %.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2024.
-
Busy address KBO
24 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
Affordable Medicines Europe from Brussel, company number BE0465125985, closed financial year 2024 with a result of € -1.2 million after tax. For that financial year Affordable Medicines Europe recorded a gross margin of € 175,155 and equity of € 466,510. Compared with financial year 2023, the result moved from € -71,393 to € -1.2 million. The company made a loss. The buffer shrank hard: equity is 72 % below last year. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 24, 2025.
€ 466,510
▼ 72% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.2 million
▼ 1540 % more loss than in 2023
Profit after tax over the fiscal year.
€ 57,574
▼ 88% vs 2023
Cash and bank balances on the last day of the fiscal year.
People and assets in 2024
2.8
▲ 0.8 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 197,761
▲ 13% vs 2023
€ 70,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 276,569
▲ 74% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 47,867
▲ 31% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 226,072 | € 170,248 | € 86,663 | € 175,155 | ▲ 102% |
| Profit after taxes | € 124,846 | € 19,946 | € -71,393 | € -1,171,044 | ▼ € 1.1 million |
| Equity | € 1,689,001 | € 1,708,947 | € 1,637,554 | € 466,510 | ▼ 72% |
| Total debts | € 148,405 | € 123,576 | € 201,486 | € 329,548 | ▲ 64% |
| Cash | € 1,648,250 | € 1,727,276 | € 468,144 | € 57,574 | ▼ 88% |
| Retained profit | € 1,689,001 | € 1,708,947 | € 1,637,554 | € 466,510 | ▼ 72% |
| Balance sheet total | € 1,837,406 | € 1,832,523 | € 1,839,040 | € 796,058 | ▼ 57% |
| Employees (FTE) | 1.9 | 1.8 | 2 | 2.8 | ▲ 0.8 |
Key figures of Affordable Medicines Europe, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Affordable Medicines Europe?
What happened at Affordable Medicines Europe in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 1.2 million. filed late Source: NBB ↗
- Martin Kriz stepped down as director. NBB
- Gian Maria Morra stepped down as director. NBB
- Wagner Flemming stepped down as director. NBB
- Thomas Brandhof stepped down as director. NBB
- Mike Goorman stepped down as director. NBB
- Tomasz Dzitko stepped down as director. NBB
- Jean-Hugues Michel stepped down as director. NBB
In short
From € 124,846 profit in 2021 to € 1.2 million loss in 2024.
Paid € 23,239 in corporate taxes since 2021.
Best year ever: 2021, with € 124,846 profit.
On average € 62,600 of value added per employee in 2024.
A new publication or filing at Affordable Medicines Europe? We notify you, reason included.
Follow Affordable Medicines EuropeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Affordable Medicines Europe is Emil Backlund.
Directors
According to the 2024 annual accounts
Emil Backlund
Membre du Conseil de Direction
since 2024
Martin Kriz
Director
since 2022 · until 2024
Gian Maria Morra
Director
since 2023 · until 2024
Wagner Flemming
Director
since 2021 · until 2024
since 2021 · until 2024
Mike Goorman
Director
since 2023 · until 2024
Tomasz Dzitko
Director
since 2021 · until 2024
Jean-Hugues Michel
Director
since 2023 · until 2024
Andrew Tittershil
Director
since 2022 · until 2024
since 2023 · until 2024
Friederike Hrubesh-Mohringer
Director
since 2021 · until 2024
Tibor Kovacs
Director
since 2021 · until 2024
Guillaume Perruchot
Vice-chairman of the board
since 2021 · until 2024
Patrick Wadding
Director
since 2021 · until 2024
Bogdan Pavel
Director
since 2021 · until 2024
Andreas Roselund
Director
since 2023 · until 2024
Andre Guergana
Director
since 2021 · until 2024
Kasper Ernest
Personne déléguée à la gestion journalière
since 2019 · until 2024
Alexandros Tsatsaronis
Director
since 2021 · until 2024
Faustas Malinauskas
Director
since 2021 · until 2024
Carlos Iglesias Jimenez
Director
since 2021 · until 2024
Jörg Geller
Chairman of the board
since 2023 · until 2024
Antonio Tito Mantero de Mendonça Alves
Director
since 2021 · until 2024
Jan de Kreij
Director
since 2021 · until 2024
Martin Satran
Director
since 2021 · until 2024
Establishments
Establishment units
Physical locations of this company
Tweekerkenstraat 26
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 24 companies are registered at this address.
All companies at this address →Mutuelle d'Allocations Familiales l'Entraide des C.H.R.
Scientific Association of European Talc Industry
SGI Europe
€ 988,649 revenue · 2025
ASSOCIATION DES TELEVISIONS COMMERCIALES ET SERVICES DE VIDEO A LA DEMANDE EN EUROPE
€ 991,275 gross margin · 2025
INDUSTRIAL MINERALS ASSOCIATION EUROPE
€ 1.6 million gross margin · 2025
+19 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
DNS
OVH DNS
Website info
Features
Security
Details
- Company number
- 0465.125.985
- VAT number
- BE 0465.125.985
- Registered office
- Tweekerkenstraat 26, 1000 Brussel
- Names & denominations
- Affordable Medicines Europe
- Enterprise type
- Rechtspersoon
- Legal form
- International non-profit association
- Legal situation
- Normale toestand
- Start date
- 11 February 1999
- Peppol
- Active · Active since 17 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering